دورية أكاديمية
Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer
| العنوان: | Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer |
|---|---|
| المؤلفون: | Ravit Edelman, Yehuda G. Assaraf, Anton Slavkin, Tamar Dolev, Tal Shahar, Yoav D. Livney |
| المصدر: | Pharmaceutics, Vol 11, Iss 5, p 216 (2019) |
| بيانات النشر: | MDPI AG, 2019. |
| سنة النشر: | 2019 |
| المجموعة: | LCC:Pharmacy and materia medica |
| مصطلحات موضوعية: | hyaluronic acid, serum albumin, Maillard conjugates, theranostic nanoparticles, CD44-targeted chemotherapy, ovarian cancer, Pharmacy and materia medica, RS1-441 |
| الوصف: | Ovarian cancer mortality is the highest among gynecologic malignancies. Hence, the major challenges are early diagnosis and efficient targeted therapy. Herein, we devised model theranostic nanoparticles (NPs) for combined diagnostics and delivery of chemotherapeutics, targeted to ovarian cancer cells. These NPs were made of natural biocompatible and biodegradable body components: hyaluronic acid (HA) and serum albumin (SA). The hydrophilic HA served as the targeting ligand for cancer cells overexpressing CD44, the HA receptor. SA, the natural carrier of various ligands through the blood, served as the hydrophobic block of the self-assembling block copolymeric Maillard-conjugates. We show the successful construction of fluorescently-labeled SA-HA conjugate-based theranostic NPs, their loading with paclitaxel (PTX) (association constant (8.6 ± 0.8) × 103 M−1, maximal loading capacity of 4:1 PTX:BSA, and 96% encapsulation efficiency), selective internalization and cytotoxicity to CD44-overexpressing ovarian cancer cells (IC50: 26.4 ± 2.3 nM, compared to 115.0 ± 17.4 of free PTX, and to 58.6 ± 19.7 nM for CD44-lacking cognate ovarian cancer cells). Fluorescein isothiocyanate (FITC) was used for in vitro imaging, whereas long wavelength fluorophores or other suitable tracers would be used for future in vivo diagnostic imaging. Collectively, our findings demonstrate that fluorescent HA-SA NPs harboring a cytotoxic drug cargo can specifically target, label CD44-expressing ovarian cancer cells and efficiently eradicate them. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1999-4923 89772458 |
| Relation: | https://www.mdpi.com/1999-4923/11/5/216; https://doaj.org/toc/1999-4923 |
| DOI: | 10.3390/pharmaceutics11050216 |
| URL الوصول: | https://doaj.org/article/9dbc2d624a6045f0bf1eb89772458900 |
| رقم الأكسشن: | edsdoj.9dbc2d624a6045f0bf1eb89772458900 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19994923 89772458 |
|---|---|
| DOI: | 10.3390/pharmaceutics11050216 |